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Summary
Histiocytic sarcoma (HS) is a rare malignant proliferation of histiocytes of uncertain molecular pathogenesis. Here, genetic
analysis of coincident loss of Pten and Ink4a/Arf tumor suppressors in the mouse revealed a neoplastic phenotype domi-
nated by a premalignant expansion of biphenotypic myelolymphoid cells followed by the development of HS. Pten protein
loss occurred only in the histiocytic portion of tumors, suggesting a stepwise genetic inactivation in the generation of HS.
Similarly, human HS showed genetic or epigenetic inactivation of PTEN, p16INK4A, and p14ARF, supporting the relevance of
this genetically engineered mouse model of HS. These genetic and translational observations establish a cooperative role
of Pten and Ink4a/Arf in the development of HS and provide mechanistic insights into the pathogenesis of human HS.
Introduction
The PTEN tumor suppressor gene is mutated in diverse human
cancers including glioblastoma, prostate cancer, endometrial
cancer, breast cancer, and anaplastic meningiomas (Li et al.,
1997; Steck et al., 1997). Mutations in PTEN are also frequently
encountered in primary leukemias and lymphomas (Sakai et al.,
1998) and are thought to contribute to tumor initiation and/or
progression in the lymphoid compartment. The PTEN gene en-
codes a dual-specificity phosphatase, whose major substrate is
phosphatidyl inositol-3,4,5-triphosphate (PIP3), a second mes-
senger molecule produced by PI3K activation following growth
factor stimulation. PIP3 in turn activates the serine-threonine
kinase PKB/AKT, a positive regulator of cell survival, prolifera-
tion, and oncogenesis (Cantley and Neel, 1999; Simpson and
Parsons, 2001). Thus, the dephosphorylation of PIP3 by PTEN
leads to decreased cell survival.
In the mouse, Pten nullizygosity leads to early embryonic le-
thality, whereas Pten heterozygosity results in lymphoid hyper-
plasia, T cell lymphomas, and endometrial, prostatic, and breast
cancers (Di Cristofano et al., 1998; Podsypanina et al., 1999;
Suzuki et al., 1998). Pten appears to play a particularly promi-
nent role in growth regulation of immunocytes, as evidenced
by the prevalence of autoimmune disorders in Pten+/2 mice
(Di Cristofano et al., 1999). Similarly, T cell-specific ablation of
a conditional Pten null allele leads to the development of CD4+
lymphomas and autoimmunity, the latter relating to impaired
thymic negative selection and peripheral tolerance (Suzuki
et al., 2001). In contrast, B cell-specific deletion of a conditional
Pten null allele impairs B cell homeostasis and immunoglobulin
class switch recombination, but does not provoke the develop-
ment of B cell lymphomas (Suzuki et al., 2003). Outside the he-
matopoietic system, there is experimental evidence that Pten
actively maintains the balance between different cell types in
the adult pancreas and that misregulation of the PI3K pathway
in centroacinar cells may contribute to the initiation of pancre-
atic carcinoma in vivo. (Stanger et al., 2005).
The overlapping reading frames in the INK4A/ARF locus
encode two distinct tumor suppressors, p16INK4A and p14ARF
(p19ARF in mice) that function as regulators of the pRB and
p53 pathways, respectively (Quelle et al., 1995; Sharpless and
DePinho, 1999). p16INK4A and other members of the INK4A
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HS in humans is a raremalignancy that is typically very aggressive andpoorly responsive to existing therapy. As themolecular etiology
of this neoplasm is not known, the development and deployment of rational targeted therapeutics have not been possible. Progress in
this area has also been hampered by a paucity of biological systems (cellular and organismal) that can validate suspected target
genes. Here, we provide genetic evidence of the cooperative interactions of the PTEN and INK4A/ARF tumor suppressor genes in
the development of human and mouse HS. Therefore, Pten+/2 Ink4a/Arf2/2 double mutant mice constitute a model system ideal for
dissecting HS pathogenesis and for testing PI3K and cdk4/6 targeted agents in this currently intractable disease.
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family inhibit G1 cyclin D-dependent kinases 4 and 6, thereby
preventing CDK4/6-directed pRB hyperphosphorylation and
blocking S phase entry. p14ARF inhibits MDM2-mediated degra-
dation of p53 and plays an important role in the apoptotic elim-
ination of aberrantly cycling cells (Quelle et al., 1995; Sharpless
and DePinho, 1999). A wide spectrum of human cancer types
exhibit INK4A/ARF inactivation, including malignant glioma,
melanoma, and non-Hodgkin’s lymphoma (Burri et al., 2001;
Ruas and Peters, 1998; Sharpless and DePinho, 1999).
In the mouse, an extensive analysis of p16INK4a and p19ARF
has revealed their key roles in the hematopoietic system. Mice
carrying a targeted deletion of the Ink4a/Arf locus that eliminates
both the p16INK4a and p19ARF proteins succumb to B cell lym-
phomas and malignant spindle cell neoplasms (Serrano et al.,
1996). Mice lacking p19ARF, yet intact for p16INK4a, develop pre-
dominantly T cell lymphomas (Kamijo et al., 1997). Similarly,
p16Ink4a-specific knockout mice show increased incidence of
spontaneous and carcinogen-induced cancers including soft-
tissue sarcomas, melanoma, and splenic histiocytic lymphomas
(Krimpenfort et al., 2001; Sharpless et al., 2001), thereby dem-
onstrating that both gene products encoded by this locus exert
important and nonoverlapping tumor suppressor roles in diverse
lineages. Of special relevance to this report, both p16INK4a and
p19ARF have been shown to constrain immortalization of bone
marrow-derived macrophages (Randle et al., 2001). Finally,
increasing Ink4a/Arf mRNA expression is a biomarker of aging
tissues including lymphoid cells (Krishnamurthy et al., 2004)
and may engender the loss of hematopoietic stem cells during
proliferative stress as evaluated by serial transplantation of
Ink4a/Arf2/2 HSCs in mice (Stepanova and Sorrentino, 2005).
Overall, the role and regulation of the p16INK4a and p19ARF in
the hematopoietic system and their interactions with other can-
cer-relevant pathways continues to be an area of active investi-
gation.
HS is a rare malignant proliferation of neoplastic cells showing
immunophenotypic and morphologic features similar to histio-
cytes (tissue macrophages) that occurs in lymph nodes, skin,
and the gastrointestinal tract and it is of unknown etiology. It is
now recognized that most cases of HS described in the past ac-
tually represented diffuse/anaplastic large B cell lymphoma, pe-
ripheral T cell lymphoma associated with hemophagocytic syn-
drome, or lymphoma with associated reactive macrophages.
Only small numbers of bona fide examples exist in the world lit-
erature (Weiss, 2001). Here, we report the functional conse-
quences ofPten and Ink4a/Arfmutations in normal development
and neoplasia of the murine hematopoietic system and provide
mechanistic insights into the pathogenesis of human HS.
Results
Impact of Pten and Ink4a/Arf tumor suppressor
mutations on the lymphoid and histiocytic compartments
Pten+/2 Ink4a/Arf+/2 mice were intercrossed to generate co-
horts of wild-type, Pten+/2, Ink4a/Arf2/2, and Pten+/2 Ink4a/
Arf2/2 mice that were monitored closely for perturbations in
the lymphoid system. Consistent with previous reports,
Pten+/2 and Ink4a/Arf2/2 littermates had a mean disease-free
survival (lack of palpable adenopathy) that averaged 52 and
29 weeks, respectively (Cline, 1994), while Pten+/2 Ink4a/
Arf2/2 mice succumbed between 10 and 32 weeks (mean 19
weeks; p < 0.001) to a rapidly progressive disease characterized
by generalized wasting and enlarged lymph nodes (Figure 1).
Figure 1. HS in Pten+/2 Ink4a/Arf2/2 mice
A:Disease-free survival analysis of wild-type (WT),
Pten+/2, Ink4a/Arf2/2, and Pten+/2 Ink4a/Arf2/2
mutant mice. Statistically significant differences
for pairwise comparison (p < 0.001) were de-
tected between cohorts.
B: Low-power photomicrographs (inserts) and
representative H&E-stained sections from WT,
Pten+/2, Ink4a/Arf2/2, and Pten+/2 Ink4a/Arf2/2
lymph nodes are shown. Arrows: tingible body
macrophages (black), reactive lymphocytes
(yellow). Scale bars: upper panels, 50 mm; lower
panels, 20 mm; inserts, 0.5 cm.
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While all mutant animals developed enlarged lymphoid tissues,
there were marked differences in lymphoid tumor histology
among the various mutant genotypes. Pten+/2 mice showed
lymphoid hyperplasia with some nodal architectural distortion,
but not effacement of normal lymphoid architecture (Figure 1B).
In agreement with these benign histological features, B and T
cell receptor gene rearrangement analyses revealed poly-
clonal/oligoclonal patterns in 30 of 31 cases examined over
a 1 year period of observation, and the sole exception was a
Pten+/2 mouse that developed a histological picture of lym-
phoma with a documented clonal T cell receptor gene rear-
rangement pattern (Table 1 and Figure S1A in the Supplemental
Data available with this article online, lane 6). Ink4a/Arf2/2 mice
showed replacement of the normal lymph node architecture by
a homogeneous population of medium-sized atypical lymphoid
cells, and a ‘‘starry sky’’ pattern was evident due to presence of
frequent mitotic figures and numerous tingible body macro-
phages (Figure 1B). According to the Bethesda guidelines for
classification of lymphoid neoplasms in mice (Morse et al.,
2002), most tumors in Ink4a/Arf2/2mice were classified as pre-
cursor B or T lymphoblastic lymphoma (LL). Flow cytometric,
immunohistochemical (Figure 2A), and gene rearrangement
studies revealed that most of the lymphomas were of B cell or-
igin, fewer were of T cell origin, and rarely biphenotypic, i.e., dis-
played surface marker expression (Figure 2A) and clonal gene
rearrangements of both T and B cell lineages (Table 1, Figure 3A,
and data not shown). Of the seven T cell lymphomas, one was
CD42CD8+, one was CD4+CD8+, and five were CD4+CD82
(data not shown).
In contrast to the single mutant mice, Pten+/2 Ink4a/Arf2/2
mice showed early lymphomatous involvement with a biphasic
histological pattern in 30 of 40 mice, consistent with both T or
B cell lymphoma and HS. Specifically, we observed dark blue
staining areas (Figure 1B) consisting of lymphoblastic cells
with phenotypes and genotypes of B cells, T cells, or B and T
cells (Figures 2A and 3A). This Pten+/2 Ink4a/Arf2/2 lymphoma
picture was similar to that described above for the Ink4a/
Arf2/2 mice, including the predominance of B cell over T cell
lymphomas (Table 1). However, a notable difference in the
Pten+/2 Ink4a/Arf2/2 cohort was the presence of light pink areas
comprised of very large cells with hyperchromatic, irregular
nuclei, clumped chromatin, prominent nucleoli, and abundant
eosinophilic cytoplasm (Figures 1 and 2A). These large cells ex-
pressed the histiocytic cell markers MAC2 and F4/80 (Figures
Figure 2. Immunophenotype of lymphomas and HS
A: Representative tumor types arising from Ink4a/Arf2/2 or Pten+/2 Ink4a/Arf2/2micewere analyzed by flow cytometry, H&E staining, and immunohistochem-
istry for B220, MAC2, and CD3 antibodies. The upper panel represents a biphenotypic LL (B220+, MAC22, CD3+). The middle panel represents a composite
lymphoma bearing areas of B cell LL (upper portion, dark blue areas; B220+, MAC22, CD32) and areas of HS (lower portion, pink light areas; B2202,
MAC2+, CD32). The lower panel represents a case of T LL (B2202, MAC22, CD3+).
B: Morphologic resemblance between Pten+/2 Ink4a/Arf2/2 mouse and human HS as seen by comparing representative examples of Pten+/2 Ink4a/Arf2/2
mouse HS (left) and human HS (right) are shown. Scale bars: 50 mm; inserts, 20 mm.
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2A and 3C and data not shown) and were negative for B cell
markers (B220 and Bcl-6), for pan-T cell markers (CD3, CD4
[variable] and CD8), and for myeloperoxidase, Gr-1, and
Mac-1 (Figures 2A, 3C, and 5A and data not shown). These
histological and immunophenotypic features resemble those
of human HS (Figure 2B). Only 4 of 40 Ink4a/Arf2/2 lymphomas
(4/40) showed a histiocytic component, and this phenotype was
limited primarily to the white pulp areas of the spleen (Table 1).
These data clearly demonstrate a change of tumor spectrum
brought about by combined Pten and Ink4a/Arf deficiency
and, together with the accelerated onset of disease in com-
pound mutant mice, indicate genetic cooperation between
Table 1. Lymphoma phenotype/genotype
Wild-type Pten+/2 Ink4a/Arf2/2 Pten+/2 Ink4a/Arf2/2
Normal 30 0 2 0
Lymphoproliferative disorder 0 31 1 3
Lymphoblastic T cell lymphoma 0 1 7 6
Lymphoblastic B cell lymphoma 0 0 24 30*
Biphenotypic B and T cell lymphoma 0 0 2 1
Histiocytic sarcoma 0 0 4 30*
Total 30 31 40 40
*The majority of Pten+/2Ink4a/Arf2/2 hematopoietic tumors (30/40) showed a biphasic pattern of both lymphoblastic lymphoma and histiocytic sarcoma.
Figure 3. Southern and Western blots of lymphomas and HS
A: Clonal B cell (BCR) and T cell (TCR) receptor gene rearrangement analysis by Southern blot using DNA isolated from WT (lymph nodes), Ink4a/Arf2/2 lym-
phomas (lanes 2 and 6) and Pten+/2 Ink4a/Arf2/2HS cases (lanes 2–4 and 7–9). Arrows indicate small clonal bands in lanes 7 and 10. Germline configuration of
the B cell receptor gene (GL-B). Germline configuration of the T cell receptor gene (GL-T). Lanes 2 and 10 show presence of clonal bands for both the B and T
cell receptor genes. Southern blot using aprobe recognizingWTand knockout forms of the Pten locus (Pten) to document zygosity. Targeted inactive allele of
Pten (KO). Note loss of the remaining WT Pten allele (lanes 4, 8, and 10).
B:Western blot demonstrating Akt activation in HS from Pten+/2 Ink4a/Arf2/2 (samples M3–M9) compared to WT spleen (lane 1) and in LL from Ink4a/Arf2/2
mice (M1 and M2) by immunoblotting with phospho-specific Akt antibodies to S473 and T308 (see text). ERK1/2 activation was assessed using phospho-spe-
cific antibodies to T202/Y204. The approximate tumor cellularity of the HS samples was 90% in M3–M7 and 70%–80% in M8 andM9—estimated by the extent of
normal tissue infiltration determined by Pten immunohistochemistry.
C: Pten immunohistochemical analysis in mouse HS. Tissue sections from one case of LL (M2) and three cases of HS were unstained or stained with MAC2 or
Pten antibodies. Note preservation of Pten immunoreactivity in M2 (same as Figure 3B) LL and loss of reactivity in HS (M3, M7, M8) (same as Figure 3B). Arrows
indicate the following: HS cells (yellow), stroma (black), normal lymphoid cells (orange). Scale bars: 50 mm.
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Pten and Ink4a/Arf mutations in lymphomagenesis and the
development of HS.
Loss of Pten and activation of Akt and Erk in HS
Southern blot analysis of the remaining wild-type Pten allele in
the lymphomas arising in Pten+/2 Ink4a/Arf2/2 mice revealed
wild-type Pten gene deletion in 13 of 40 cases (33%) (Figure 3A).
The remaining faint wild-typePtenband likely represents aminor
proportion of nonneoplastic cells as documented by immuno-
histochemistry with Pten antibodies and argues thatPten reduc-
tion to homozygosity occurs in both the histiocytic and the
lymphoblastic components (see below). Notably, in contrast to
tumors arising in Pten+/2 Ink4a/Arf2/2 mice, 31 of 32 of the
lymphoproliferative lesions arising in Pten+/2 mice retained the
wild-type Pten allele, with the sole exception of a lymphoma
arising in an aged mouse (Figure S1A, lane 6).
Aberrant activation of the PI3K/Akt signaling pathway, leading
to uncontrolled cell growth, proliferation, and survival is well
documented in a wide variety of cancers and is thought to be
the major mechanism by which loss of Pten promotes tumor
progression (Cantley and Neel, 1999). Since the development
of HS was seen only in those Ink4a/Arf2/2 mice also missing
one Pten allele, we hypothesized that reduction or loss of Pten
function, leading to hyperactivation of Akt signaling, may be
an important feature of these tumors. Full activation of Akt is
dependent upon phosphorylation of two residues, T308 in the
activation loop and S473 in the hydrophobic motif (Vanhaese-
broeck and Alessi, 2000). Western blotting with phospho-spe-
cific antibodies against both of these residues clearly indicated
increased Akt activation in the majority of HS samples, while
lymphomas arising in Ink4a/Arf2/2 mice show no increase in
Akt phosphorylation when compared with normal tissue from
wild-type mice (Figure 3B). Examination of Pten levels in these
samples (Figure 3B), with a sole exception in sample M8, sug-
gested a loss of Pten protein from the majority of HS samples,
which can largely be attributed to loss of heterozygosity in the
tumor cells as determined by Southern blot analysis (Figure 3A).
These results prompted us to investigate the levels of Pten pro-
tein expression in HS samples by immunohistochemistry (Fig-
ure 3C). Remarkably, in all samples analyzed, histiocytic tumor
cells lacked immunoreactivity for Pten, while stromal cells and
some contaminating normal lymphoid cells retained Pten signal
(Figure 3C). These results demonstrate that the Pten band seen
in sample M8 byWestern blot analysis (Figure 3B) is likely due to
infiltration of normal cells in this tumor, which accounts for up to
30% of the cellularity in this sample. These results also demon-
strate that loss of Pten function is a required mechanism for the
development of HS. Interestingly, sample M7 revealed preser-
vation of the wild-type allele by Southern blot analysis (data
not shown), indicating that additional mechanisms for Pten
loss may operate in some tumor samples. Sequence analysis
of Pten encoding sequences in HS samples M3–M9 did not de-
tect any mutations, further indicating that other epigenetic
events may lead to Pten loss in some cases of HS (Table S1A
and data not shown).
There exists an intimate relationship between PI3K/Akt and
RAS-MAPK pathways, and the latter is similarly activated in
a wide range of tumors (Sebolt-Leopold and Herrera, 2004).
We observed an increase in phosphorylation of both ERK1
and ERK2 (p44 and p42) in several of the HS samples when
compared both to normal tissues from wild-type mice and to
lymphomas from Ink4a/Arf2/2 mice. The expression level of
ERK1 is also elevated in several of the HS samples (Figure 3B).
Thus, in addition to increased signaling through the PI3K/Akt
pathway, the RAS-MAPK pathway appears to be hyperacti-
vated in HS, as evidenced by increased expression and phos-
phorylation of ERK. This biochemical finding recalls previous
observations of occasional HS cases in pEm-Ras transgenic
mice (Haupt et al., 1992).
Cell biological and developmental impact of dual Pten
and Ink4a/Arf inactivation in murine lymphoid
and histiocytic cells
To understand better the role of Pten and Ink4a/Arf in the devel-
opment of the aforementioned neoplastic phenotypes, we as-
sessed the cellularity, proliferation, and apoptosis profiles of
the lymphoid and histiocytic compartments in prelymphoma-
tous wild-type and mutant samples (Figure 4, Figure S1, and
Tables S2 and S3). Through 8 weeks of age, all mutant mice
demonstrated progressive lymphoid organ enlargement and
increased total cellularity in the spleen that was more severe in
Pten+/2 Ink4a/Arf2/2 mice compared with single mutant and
wild-type control littermates (Table S2). At 20 weeks of age, his-
tologic surveys of lymph nodes, thymuses, and spleens of
Pten+/2 Ink4a/Arf2/2, but not single mutant or wild-type mice,
revealed significantly increased numbers of lymphatic follicles
containing large irregularly shaped germinal centers in lymph
nodes, prominent B cell infiltration of the thymicmedulla, and in-
creased white pulp areas with frequent, prominent germinal
centers and marginal zone areas in the spleen (Figure 4). More-
over, flow cytometric analyses of thymuses revealed an expan-
sion of B220+ B cells relative to CD3+ T cells in Pten+/2 and
Pten+/2 Ink4a/Arf2/2 mutant strains, suggesting that Pten hap-
loinsufficiency is the primary driver of this B cell phenotype
(Table S3 and data not shown). In contrast, the phenotype of
frequent germinal centers appears to be related to the Ink4a/
Arf deficiency as it is correlated with the Ink4a/Arf2/2mutant ge-
notype and not Pten status (Figure 4).
Further assessment of peripheral B and T cells included mito-
gen stimulation assays of total lymph node mononuclear cells
derived from the various genotypes. Relative to wild-type
controls, Pten+/2 and Ink4a/Arf2/2 lymphoid cells showed in-
creased proliferation upon exposure to the polyclonal B cell
and macrophage activator LPS, or to the T cell activators CD3
and CD28 (Figure S1B), findings consistent with previous re-
ports establishing a role of Pten and Ink4a/Arf in the control of
lymphoid cell proliferation (Di Cristofano et al., 1999; Hoang-
Xuan et al., 2001; Serrano et al., 1996; Suzuki et al., 2001,
2003). Compared with these single mutants, Pten+/2 Ink4a/
Arf2/2 lymphoid cells exhibited increasedmitogen-induced pro-
liferation as measured by thymidine incorporation (Figure S1B).
Analysis of apoptotic indices in prelymphomatous lymph nodes
revealed significantly fewer apoptotic lymphoid cells in Pten+/2
Ink4a/Arf2/2 (39 per 10 HPF) and Pten+/2 (38 per 10 HPF) sam-
ples compared to wild-type (70 per 10 HPF) or Ink4a/Arf2/2mice
(65 per 10 HPF) (Figure S1C), observations consistent with pre-
viously reported roles of Pten in lymphoid survival (Podsypanina
et al., 1999; Suzuki et al., 2001).
Since the macrophage lineage is the presumed origin of HS,
this lineage was examined in the prelymphomatous tissues of
the various genotypes. MAC2 antibody staining revealed signif-
icant expansion of the macrophage population in Pten+/2 Ink4a/
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Arf2/2 spleens relative to wild-type, Pten+/2, and Ink4a/Arf2/2
spleens, consistent with cooperative roles of Pten and Ink4a/
Arf in restricting macrophage growth (Figure 4). Expansion of
histiocytes was observed in other Pten+/2 Ink4a/Arf2/2 tissues,
including the liver (data not shown). This result is particularly
interesting in light of the recent observation highlighting the
role of p16INK4a and p19ARF in immortalization of murine bone
marrow-derived macrophages (Randle et al., 2001). As shown
in Figure 5B, flow cytometric analysis of premalignant bonemar-
row mononuclear cells revealed an expanded population of
mature myeloid and macrophages as well as a population of
biphenotypic B220+CD117+ cells in Pten+/2 Ink4a/Arf2/2 mice,
but not in control and Ink4a/Arf2/2 mice (Figure 5B), pointing
to a role of Pten in controlling the proliferation and differentiation
potential of a common myelolymphoid progenitor (Figures 5C
and 5D).
PTEN, p16INK4A, and p14ARF are targeted in a subset
of human HS
Our findings of significant expansion of macrophage popula-
tions and increased incidence of HS in Pten+/2 Ink4a/Arf2/2
mice prompted us to investigate the status of PTEN and
p16INK4A in human HS (Table 2 and Figure 6), a rare human neo-
plasm with only a limited number of cases reported in the world
literature. Immunohistochemical analysis was performed using
clinically standardized PTEN and p16INK4A antibodies on a panel
of ten archival cases of human HS (Hornick et al., 2004). Loss of
immunoreactivity for either PTEN or p16INK4A alone was seen in
four and five cases, respectively. Three of the ten cases showed
concomitant lack of immunostaining for both PTEN and
p16INK4A, while four of the ten cases showed intact staining for
both proteins (Table 2, Figure 6A, and data not shown). The
presence of reactivity in nonlesional tumor cells served as inter-
nal positive controls.We further analyzed the activation status of
Akt proteins in human HS using clinically standardized p-Akt
antibodies. Most human HS cases revealed increased levels
of p-Akt in the histiocytic tumor cells, while in adjacent normal
cells p-Akt was either barely detectable or not detected at all
(Table 2 and Figure 6A). These results indicate that, in human
HS, Akt phosphorylation is a general pathogenetic event and
suggest that additional mechanisms besides PTEN inactivation
can lead to Akt activation, including among others changes in
Src activity, PTEN expression, PI3K activity, or receptor tyrosine
kinase signaling (Hodgson et al., 2005; Lu et al., 2003; Nagata
et al., 2004; Shekar et al., 2005; Wang et al., 2005). Nested
PCR enabled further molecular investigations of laser-captured
tumor cells for six of ten tumors (Table 2 and Figure 6B). Using
specific oligonucleotides to amplify each of the nine exons of
PTEN (Table S1), no amplification of exons 6 to 9 in tumor H3
was seen, nor amplification of all nine exons in tumor H6. These
PTEN gene deletion patterns are not related to DNA quality
Figure 4. B cell and histiocytic hyperplasia
Lymphoid tissues from 20-week-old WT, Pten+/2, Ink4a/Arf2/2, and Pten+/2 Ink4a/Arf2/2mice were analyzed by H&E staining and immunoperoxidase studies
using MAC2 antibodies (far right column). Note frequent enlarged germinal centers (white arrows) in Pten+/2 Ink4a/Arf2/2 lymph node, thymic medulla, and
splenic white pulp. Note extensive lymphoid infiltration of thymic medulla in Pten+/2 and Pten+/2 Ink4a/Arf2/2mice and expanded population of MAC2+ his-
tiocytes (black arrows) in Pten+/2 Ink4a/Arf2/2 splenicmarginal zones (yellow arrows). Me,medulla; Co, cortex;WP, white pulp; RP, red pulp. Scale bars: lymph
node and thymus, 0.5 mm; spleen, 125 mm.
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issues (see below) and concur with the lack of PTEN protein sig-
nals above (Table 2, Figure 6B, and data not shown). In the case
of p16INK4A and p14ARF, all samples showed the presence of
amplification products for all four coding exons, and these
fragments were determined to be free of point mutations upon
sequence analysis (Table 2, Figure 6B, and data not shown).
In addition, TP53 immunohistochemistry revealed low or unde-
tectable expression in six of nine human samples analyzed
Figure 5. Proposed model for PTEN and INK4A/ARF function in hematopoiesis
A: Analysis of myeloperoxidase (My), B220, CD3, and MAC2 antibodies on paraffin-embedded tissue sections from mouse HS. Control stain without primary
antibody. Scale bars, 50 mm.
B: Flow cytometric analysis of bone marrow mononuclear cells derived from mice. Note expanded populations of Gr-1+ and B220+CD117+ cells in Pten+/2
Ink4a/Arf2/2 mice.
C: Analysis of PTEN expression in HS. Note presence of immunoreactivity in lymphoblastic cells but complete absence of reactivity in histiocytic cells. H&E
inserts. Scale bars: upper panel, 125 mm; lower panel and inserts, 20 mm.
D: Proposed model for PTEN and INK4A/ARF function in hematopoiesis. Arrows indicates enhanced populations.
Table 2. Human histiocytic sarcoma immunohistochemical and molecular analysis
Tumor PTEN p16INK4A p-Akt TP53* PTEN deletion p16INK4A promoter methylation p14ARF promoter methylation
H1 +++ +++ +++ ++++ N N N
H2 2 2 +++ + N N Y
H3 2 2 +++ ++ Y Y Y
H4 + + ND ND N N Y
H5 2 + ++ + N N Y
H6 2 2 ++ +++ Y Y N
H7 +++ +++ +++ ++ ND N Y
H8 2 ++ ++ ++ ND N Y
H9 ++ ++ +++ + ND N Y
H10 + 2 ++ ++++ ND N N
An arbitrary scale for grading immunohistochemical signal was usedwith ‘‘++++’’ as high expression and ‘‘2’’ as no expression. *For TP53 immunostains, a +++
value was assigned to control normal histiocytes. Molecular analysis of PTEN in H7–H10 was not determined (ND) due to insufficient DNA.
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(H2, H3, H5, H7–H9); moreover, sequence analysis did not de-
tect any mutations in exons 5 to 9 in TP53 encoding sequence,
including the two samples with moderate expression (Figure 6A,
Table 2, Table S1, and data not shown). Finally, using methyla-
tion-specific PCR (MSP) (Esteller et al., 2001; Herman et al.,
1996), p16INK4A promoter methylation was evident in two tumors
(H3 and H6), while p14ARF promoter methylation was evident in
seven of ten tumors (H2–H5, H7–H9). Very low levels or com-
plete absence of p14ARF promoter methylation was observed
in three tumors (H1, H6, and H10) (Figure 6C and Table 2). In
agreement with the role of p14ARF in blocking MDM2-mediated
degradation of p53 (Pomerantz et al., 1998; Zindy et al., 2003),
the levels of p14ARF promoter methylation were inversely corre-
lated with p53 immunoreactivity (Table 2). When using PCR oli-
gos to detect unmethylated DNA promoter sequences, no PCR
products were detected in the methylated positive control
(Figure 6C). These molecular findings, coupled with genetic ob-
servations in the Pten+/2 Ink4a/Arf2/2 mice, support a model in
which inactivation of PTEN, p16INK4A, and p14ARF tumor sup-
pressors andmost likely their linked genetic elements are critical
steps in the pathogenesis of human HS.
Discussion
In this study, we have investigated the genetic interactions of the
Pten and Ink4a/Arf tumor suppressors in normal and neoplastic
process in the hematopoietic system. These studies have re-
vealed the presence of expanded populations of lymphocytes
and histiocytes with a significant reduction in lymphoid tumor
latency and a dramatic increase in the incidence of HS in com-
pound Pten and Ink4a/Arfmutant mice. Correspondingly, analy-
sis of the targeted lineages during the premalignant phase sug-
gests that Pten and Ink4a/Arf mutations impact the control of
proliferation and apoptosis, resulting in an expansion of the in-
volved cell populations. Notably, consistent with the resultant
neoplastic phenotypes, Pten and Ink4a/Arfwere shown to serve
Figure 6. Immunohistochemistry and methylation analysis
A: Analysis of H&E, PTEN, p16INK4A, p-Akt, and TP53 antibodies on paraffin-embedded tissue sections from human HS. Note lack of immunoreactivity of tumor
cells for PTEN antibodies (H3 and H5) or p16INK4A antibodies (H5). Internal positive control, stromal cells (black arrows). Scale bars: H&E, PTEN, and p16INK4A,
125 mm; p-Akt, 50 mm; TP53, 20 mm; inserts, 25 mm.
B: DNA was isolated from paraffin-embedded tissues and nested PCR-amplified products using a set of specific primers for each of nine exons of PTEN and
each of four exons of p16INK4A/p14ARF. Note lack of PCR amplification of PTEN exons 6-9 in tumor H3 and exons 1-9 in tumor H6.
C: DNA from primary tumors was subjected to methylation-specific PCR amplification using methylated (M) or unmethylated (U) p16INK4A- or p14ARF-specific
primer sets. Note the presence of PCR products using p16INK4A- or p14ARF-methylated primers from tumors H3 and H6 and H2, H4, H5, and H7–H9, respectively.
Control male human DNA (Co); no DNA (H2O); unmethylated DNA (2); Sss I (CpG) methylase-treated DNA (+).
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distinct and cooperative roles in hematopoietic lineage develop-
ment with a notable expansion in mature B lymphocytes, granu-
locytes, and macrophages/histiocytes as well as biphenotypic
B220+CD117+ cells in Pten Ink4a/Arf mutant mice. Importantly,
the genetic and biochemical evidence of a cooperative role for
Pten and Ink4a/Arf in constraining HS development translated
to human HS wherein PTEN and p16INK4A were also found to
be extinguished. Thus,murinemodeling of disease has provided
mechanistic insights into pathogenesis of human HS.
Deficiency of either Pten or Ink4a/Arf leads to B cell expan-
sion, proliferation, and/or apoptotic defects of T cells (Figure 4,
Figure S1, and Tables S2 and S3) (Di Cristofano et al., 1999; Ka-
mijo et al., 1999; Podsypanina et al., 1999; Serrano et al., 1996;
Sharpless et al., 2001, 2004; Suzuki et al., 2001, 2003). How-
ever, Pten and Ink4a/Arf appear to play cell-specific tumor sup-
pressor roles in the hematopoietic system, as evidenced by
markedly different tumor spectra. Pten+/2 mice rarely develop
lymphomas and instead sustain a lethal lymphoproliferative
condition with histological and immunophenotypic features
characteristic of certain autoimmune diseases (Figure 4) (Di
Cristofano et al., 1999). Moreover, mice with B cell-specific ho-
mozygous deletion of Pten have a low incidence of lymphoma
despite elevated levels of autoantibodies and a greatly in-
creased B cell population (Suzuki et al., 2003). These observa-
tions are consistent with a critical role of Pten in the regulation
of immune recognition (Di Cristofano et al., 1999) and B cell ho-
meostasis but not in the suppression of B cell malignancy
(Figure S1A) (Suzuki et al., 2003). On the other hand, the rare
lymphomas that do arise in Pten+/2 animals possess a T cell
phenotype and show LOH of the Pten wild-type allele (Fig-
ure S1A) (Suzuki et al., 1998). In addition, T cell-specific deletion
of Pten leads to the development of T cell lymphomas and de-
fects in central and peripheral tolerance, linking autoimmunity
and lymphomagenesis (Suzuki et al., 2001). Overall, these re-
sults indicate that the development of rare lymphomas and the
onset of autoimmune disease inPten+/2mice are primarily asso-
ciated with an intrinsic defect in the T cell compartment or are
secondary to impaired T cell/B cell interactions, which may
lead to defects in central or peripheral tolerance. Hence, Pten
has a cell type-specific tumor suppressor activity in the lym-
phoid compartment. In T cells,Pten appears to behave as a clas-
sic tumor suppressor, undergoing ‘‘two-hit’’ inactivation (Suzuki
et al., 2001). In B cells, Pten haploinsufficiency or homozygous
inactivation causes nonclonal B cell growth but does not lead
to B cell lymphomas (Suzuki et al., 2003); rather, these data
prompt speculation that Pten haploinsufficiency promotes im-
mune dysfunction that facilitates lymphomagenesis in the T
cell compartment.
Ink4a/Arf is required for suppression of both T and B cell ma-
lignancies (Table 1) (Kamijo et al., 1999; Kamijo et al., 1997; Ser-
rano et al., 1996; Sharpless et al., 2001). Notably, despite the
role of Pten in homeostasis of these compartments, Pten het-
erozygosity does not appear to strongly synergize with Ink4a/
Arf deficiency in promoting T or B cell lymphomas. Instead,
there is an increased incidence of HS bearing remarkable path-
ological similarity to the rare human disease (Table 1 and Fig-
ure 2B). These tumors are thought to arise frommacrophage lin-
eages, a compartment that is expanded in prelymphomatous
Pten+/2 Ink4a/Arf2/2 mice (Figure 4). Of potential relevance,
mice lacking p19ARF but expressing functional p16INK4a develop
lymphomas, predominantly of T cell origin (Kamijo et al., 1999);
however, when crossed to Bax deficient mice, a proportion (2 of
25) of Arf null animals developed HS (Eischen et al., 2002). The
emergence of comparable tumor phenotypes in these models
likely reflects disruption of common biochemical pathways.
Pten and Bax deficiency may have overlapping roles in the gen-
esis of HS, since Pten loss promotes activation of Bcl-xl and
Bcl2, which are antiapoptotic antagonists of Bax (Huang et al.,
2001). The Ink4a/Arf locus also appears to be of particular im-
portance in macrophage biology, as evidenced by the require-
ment of dual Ink4a and Arf inactivation to enable immortalization
of this lineage (Randle et al., 2001). Given these data and the
very high penetrance of HS in our cohort harboring inactivation
of both Ink4a and Arf, one might predict that p16INK4amay be in-
activated in the Arf2/2 Bax2/2 tumors (Eischen et al., 2002).
Our results suggest that Pten and Ink4a/Arf are required at dif-
ferent stages during hematopoiesis and are consistent with
a model of hematopoietic differentiation slightly different from
the currently accepted model (Figure 5D) (M. Lu et al., 2002).
INK4a/ARF appear to be primarily involved in controlling the
proliferative and/or differentiation potential of a ‘‘common T
andBcell lymphoid progenitor (p-TB)’’ and aminor role in amye-
lolymphoid progenitor (p-MTB) (Lacaud et al., 1998). Our data
are also consistent with a model in which a functional Pten
gene is required for the proper development of granulocytes
and macrophages from a myelolymphoid progenitor (p-MTB)
(Figure 5D). The fact that erythroid lineage neoplasms have
not been identified in Pten+/2, Ink4a/Arf2/2, or Pten+/2 Ink4a/
Arf2/2 mice is consistent with a lack of role for Pten and
INK4a/ARF at the level of pluripotent hematopoietic stem cells
(HSCs). The development of biphenotypic lymphomas with cells
expressing both T and B cell differentiation markers but not my-
eloid and histiocytic markers in Ink4a/Arf2/2 mice suggest the
existence of a common T and B cell progenitor (p-TB) which is
dependent on INK4a/ARF in restricting proliferation and/or dif-
ferentiation toward B or T lymphocytes (Figure 5D). The devel-
opment of HS at low frequency in Ink4a/Arf2/2 is also consistent
with a minor role of INK4a/ARF in restricting differentiation of the
p-MTB progenitor toward myeloid cells and histiocytes (p-M). In
addition, themarked increase in HS, but no change in total num-
bers of T and B cell neoplasms in Pten+/2 Ink4a/Arf2/2 mice as
compared with Ink4a/Arf2/2 mice, and the presence of ex-
panded populations of biphenotypic B220+CD117+ myelolym-
phoid cells in Pten+/2 Ink4a/Arf2/2 but not in Ink4a/Arf2/2 mice
point to a role of Pten in restricting differentiation of the p-
MTB toward histiocytes and myeloid cells. These results docu-
ment overlapping and nonoverlapping roles of PTEN and INK4A/
ARF in the process of hematopoietic diversification, support the
existence of myelolymphoid progenitor (p-MTB), and suggest
the existence of a common T and B cell progenitor (p-TB), which
may explain the rare occurrence of acute leukemia of ambigu-
ous lineage or biphenotypic acute leukemias in the clinical prac-
tice (Brunning, 2003).
Previous studies have documented the development of ha-
martoma-like, hyperplastic-dysplastic changes in the prostate,
skin, and colon of Pten+/2 mice, and these changes appear to
be associated with retention of the remaining allele of Pten (Di
Cristofano et al., 1998). In our studies, Pten+/2 mice did not
show any evidence of histiocytic hyperplasia, which was only
detected in young, pre-HS Pten+/2 Ink4a/Arf2/2 mice, support-
ing the idea that certain compartments such as the myelolym-
phoid and histiocytic compartments are less affected by Pten
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dose reduction and require the addition of p16INK4a or p19ARF
deficiency to elicit a neoplastic phenotype. Contrary to pre-HS
Pten+/2 Ink4A/Arf2/2mice, almost all mouse HS cases analyzed
showed LOH for Pten, indicating that full HS development in
mice commonly occurs in the complete absence of Pten. There-
fore, it seems plausible that the expansion of myelolymphoid
precursors in the setting of Pten heterozygosity and Ink4a/Arf
nullizygosity generates a pool of cells at risk for additional trans-
forming events.
Additional insights into the basis for the cooperative interac-
tions between Pten and Ink4a/Arf derive from proviral insertional
mutagenesis studies in Ink4a/Arf2/2 mice (Lund et al., 2002). In
that study, 80% of Ink4a/Arf2/2mice infected with Moloney mu-
rine leukemia virus (MoMuLV) developed lymphomas, and ap-
proximately 55% of these mice also developed HS. While the
Pten was not targeted for proviral insertional inactivation, there
were numerous events targeting components of the PI3K path-
way (Lund et al., 2002). Remarkably, three retroviral insertions
target phosphatase genes. The Ptpn1 and Hcph genes have
been proposed to activate Src through removal of an inhibitory
tyrosine phosphate within the Src-homology 2 (SH2) domain.
Importantly, in the context of PI3K pathway, activation of Src
is known to inactivate PTEN via phosphorylation (Lu et al.,
2003; Nagata et al., 2004). The other insertion targeted the
Dusp5 gene encoding a dual-specificity protein phosphatase,
which is thought to negatively regulate the activity of the ERK1
MAP kinase (Ishibashi et al., 1994) and consistent with the
known links between the RAS-MAPK and PI3K pathways (Pan-
dey et al., 1999).
On the molecular level, a proportion of the HS cases in our co-
hort lost the wild-type Pten allele. These changes were associ-
ated with aberrant activation of the PI3K/Akt signaling pathway
as well as the RAS-MAPK pathway, as evidenced by increased
levels in phosphorylation of Akt and both ERK 1 and ERK 2 (p44
and p42). In humans, HS is a rare malignant proliferation of cells
showing morphologic and immunophenotypic features similar
to those of mature tissue histiocytes. This neoplasm is typically
very aggressive and poorly responsive to existing therapy and is
of unknownmolecular etiology (Banks andWarnke, 2001; Horn-
ick et al., 2004). The resemblance between the phenotype and
the clinical behavior of the neoplasms arising in Pten+/2 Ink/
Arf2/2 mice and HS in humans is consistent with cooperative
roles of PTEN and INK4A/ARF tumor suppressors or linked ge-
netic elements in the pathogenesis of this poorly understood hu-
man condition. Further corroboration of this genetic interaction
was secured in translational studies documenting PTEN,
p16INK4A, and p14ARF loss by deletion of PTEN genomic se-
quences and p16INK4A and/or p14ARF promoter region hyperme-
thylation in a subset of tumors, while Akt activation appeared as
a common mechanism detected in most human tumors. These
results suggest molecular heterogeneity of human HS andmany
putative mechanisms leading to Akt activation, and we cannot
exclude the possibility that the human disease comprises dis-
tinct human HS subsets that are not distinguished by current
morphological and marker criteria. In the remaining samples
with intact PTEN and p16INK4A expression, it is reasonable to as-
sume that other components of the p16-Rb, Arf-p53, and PI3K-
PTEN pathways are targeted as suggested by the occurrence of
HS in the Arf2/2 Bax2/2 model and the MoMuLv mutagenesis
studies in Ink4a/Arf2/2 mice. Based upon the genetic and bio-
chemical findings of our study, we propose that emerging
PI3K, RAS/MAPK, and cdk4/6 inhibitors may provide effective
targeted therapies for this currently intractable disease.
Experimental procedures
Mutant mice
Pten and Ink4a/Arf mutant mice were produced as described elsewhere
(Podsypanina et al., 1999; Serrano et al., 1996) and maintained on a mixed
FVB/nC57BL/6 background. Mice heterozygous for Pten and Ink4a/Arf mu-
tant alleles were intercrossed to generate all of the genotypes analyzed in
this study and maintained on a mixed FVB/nC57BL/6 background. During
an observation period of 60 weeks, all wild-type control littermates remained
tumor free. All animal experiments were approved by and conform to the
standards of the Institutional Animal Care and Use Committee at the Dana-
Farber Cancer Institute.
Histology, TUNEL assay, immunohistochemistry, and flow
cytometry
Formalin-fixed tissues were embedded in paraffin, sectioned, and stained
with H&E. Apoptotic cells were detected with the Apoptag assay from Inter-
gen. Tissue sections were incubated with 5 mg/ml of primary antibodies or
a corresponding IgG fraction of preimmune serum in 3% BSA-PBS blocking
solution for 16 hr at 4ºC. Anti-mouse MAC2 monoclonal antibody was
obtained from Cedarlane. Anti-mouse CD45R (clone RA3-6B2) was obtained
from Pharmingen. Anti-human CD3 (MCA1477) and anti-mouse F4/80
(MCAP497) antibodies were obtained from Serotec. Anti-mouse Bcl-6
(N-3) antibody was obtained from Santa Cruz Biotechnology. Anti-PTEN
(clone 6H2.1) was from Cascade Bioscience. Primary antibodies were visu-
alized with the corresponding biotinylated antibody coupled to streptavi-
din-peroxidase complex from Vector Labs. Flow cytometry was done using
a Coulter Epics Profile II flow cytometer and cell sorter. Lymphoid cells
were prepared according to standard procedures, and 106 cells per reaction
were incubated with antibodies for 30 min on ice and resuspended in 500 ml
of 2% paraformaldehyde. Anti-mouse CD3 (145-2C11), CD4 (L3T4), CD8
(Ly-2), CD45R/B220 (RA3-6B2), IgM, Mac-1, CD117 (2b8), Gr-1 (RB6-8C5),
and p16 (clone G175-405) antibodies were from Pharmingen.
In vitro proliferation assays
Total single cell suspensions from 6- to 8-week-old lymph nodes were pre-
pared according to standard procedures, and 2 3 105 cells were plated in
triplicate in 96-well plates and stimulated with LPS (20 mg/ml) or CD3
(10 mg/ml) with CD28. After 48 hr of stimulation, the cells were pulsed with
[3H] thymidine for the final 16 hr of growth, and incorporated [3H] thymidine
was measured. Results are expressed as the arithmetic mean 6 SD of trip-
licate cultures. Similar results were obtained in three independent experi-
ments.
Western blotting analysis
Whole-cell extracts from 6- to 8-week-old mouse single cell suspensions of
lymph node cells or snap-frozen lymphomas were prepared in the presence
of 1 mM orthovanadate, 5 mM NaF, and protease inhibitors. Samples were
mixed with 43 NuPAGE loading buffer containing 50 mM DTT and heated
at 70ºC for 10 min before being loaded into 5%–12% Bis-Tris NuPAGE
gels. Proteins were transferred to nitrocellulose membranes, blocked in
TBS containing 0.1%Tween 20 and 5%nonfat milk, and incubated overnight
at 4ºC with primary antibodies. Rabbit monoclonal p-Akt (T308 and S473),
rabbit polyclonal total Akt, p-ERK1/2 (T202/Y204), and total ERK1/2 anti-
bodies were from Cell Signaling Technology. Anti-PTEN (HRP-conjugated
A2B1) was fromSanta Cruz, and the b-Actin antibody, used as a loading con-
trol, was a gift fromDon Cleveland (LICR, University of California, San Diego).
HRP-linked anti-mouse and anti-rabbit were used for secondary antibodies.
Southern blot analysis
Genomic DNA was isolated by the Puregene DNA isolation system (Gentra
Systems). Southern blot analysis for the loss of Pten gene was done as de-
scribed elsewhere (You et al., 2002). For the T cell receptor gene rearrange-
ment studies, the DNA was digested with BglII restriction enzyme, and as
a radiolabel probe, a 1.6 BamHI-KpnI genomic fragment downstream and
adjacent to the mouse TCR Jb1 gene segment was used. For the B cell
receptor gene rearrangement studies, the DNA was digested with EcoRI
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restriction enzyme and as a radiolabeled probe; a 1.9 BamHI-EcoRI genomic
fragment downstream and adjacent to the mouse heavy chain locus JH seg-
ment was used.
Laser capture microdissection, DNA preparation, bisulfite
modification, PCR amplification, and genomic sequencing
Laser capture microdissection (LCM) was performed on H&E-stained slides.
Histiocytes were microdissected using the PixCell II Laser Capture Microdi-
section System (Arcturus Bioscience). About 5000 cells were digested with
1 mg/ml proteinase K at 37ºC for 16 hr and then heated at 94ºC for 10 min.
Onemicroliter of the supernatant was used as template for nested PCR using
specific primer pairs (Table S1), and the PCR products were subjected to
both agarose electrophoresis and sequencing. LCM was repeated for all
specimens to verify the results. The remaining DNAwas subjected to bisulfite
modification as described (Herman et al., 1996) and used for methylation-
specific PCR of p16INK4A (Herman and Baylin, 2003) and p14ARF (Esteller
et al., 2001) promoter sequences (Table S1).
Supplemental data
The Supplemental Data include one supplemental figure and three supple-
mental tables and can be found with this article online at http://www.
cancercell.org/cgi/content/full/9/5/379/DC1/.
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